Mobius Therapeutics

Mobius Therapeutics is a pharmaceutical company focusing on perioperative solutions in ophthalmology, dedicated to enhancing patient care and safety during ocular surgeries. Founded in 2006 in St. Louis, US, Mobius Therapeutics specializes in innovative pharmaceuticals for ophthalmic applications. The company has not undergone any significant pivots in strategy.

The firm was established by Ed Timm, who is also the current CEO. Mobius has raised a total of USD 5. 00 mn through 6 different deals, with its most recent funding round, a Series B, occurring on October 10, 2013, backed by Cultivation Capital. Mobius Therapeutics specializes in perioperative pharmaceuticals specifically designed for ophthalmology, aiming to enhance patient care, access, and provider safety.

Their core product offerings include innovative ophthalmic solutions that address the challenging needs present in the perioperative environment. These products are intended for use by healthcare providers, particularly ophthalmologists and surgical centers, who require reliable pharmaceutical interventions during ocular surgeries. Mobius Therapeutics primarily serves markets across the United States, providing their products to hospitals, outpatient surgical facilities, and ophthalmology practices, thereby ensuring that end-users receive optimal pharmaceutical support during surgical procedures. The revenue generation model for Mobius Therapeutics is based on direct transactions with healthcare providers, including hospitals and surgical centers.

Sales occur through various channels, including direct-to-consumer approaches, where providers order necessary products via phone, fax, email, or an online store. The structured pricing is tailored to individual products, potentially including flagship offerings that cater specifically to perioperative needs in ophthalmology. The company's revenue streams are bolstered through repeat orders and long-term partnerships with healthcare facilities that rely on their specialized pharmaceutical solutions. Mobius Therapeutics is focused on developing new ophthalmic products aimed at enhancing surgical outcomes, with plans for product launches in the upcoming years.

The company is also exploring expansion into additional markets within the United States to reach more healthcare providers. The recent Series B funding of USD 5. 00 mn will support these initiatives, facilitating the development of new products and aiding in the expansion efforts.